Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Increase in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 29,800 shares, a growth of 24.7% from the March 15th total of 23,900 shares. Based on an average trading volume of 23,500 shares, the short-interest ratio is currently 1.3 days. Currently, 3.4% of the shares of the stock are sold short.

Virpax Pharmaceuticals Stock Performance

Shares of VRPX opened at $3.55 on Friday. The stock has a 50 day moving average price of $3.77 and a 200 day moving average price of $4.75. Virpax Pharmaceuticals has a one year low of $2.40 and a one year high of $11.77. The stock has a market capitalization of $4.16 million, a price-to-earnings ratio of -0.30 and a beta of 1.38.

Institutional Investors Weigh In On Virpax Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citigroup Inc. acquired a new stake in shares of Virpax Pharmaceuticals in the first quarter valued at about $27,000. Renaissance Technologies LLC grew its stake in Virpax Pharmaceuticals by 29.8% during the 2nd quarter. Renaissance Technologies LLC now owns 203,200 shares of the company’s stock valued at $341,000 after acquiring an additional 46,600 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Virpax Pharmaceuticals by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 370,884 shares of the company’s stock valued at $441,000 after acquiring an additional 28,907 shares during the last quarter. Institutional investors and hedge funds own 32.23% of the company’s stock.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.